Danelle Johnston, MSN, RN, ONN-CG, OCN, of AONN+ Appointed to the Biden Cancer Initiative Advisory Committee

May 2018 Vol 9, No 5

Categories:

In the News
Kristin Siyahian

The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the appointment of its Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives, Danelle Johnston, MSN, RN, ONN-CG, OCN, to the Biden Cancer Initiative Advisory Committee.

The mission of the Biden Cancer Initiative is to develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes. Vice President Joe Biden and Dr Jill Biden, cochairs of the initiative’s Board of Directors, have assembled a leadership team of experts in the fields of medical research, patient care, information technology, finance, management, patient engagement, patient experience, and public policy. The initiative will work with patients and patient organizations, cancer researchers, cancer centers, research universities, governments, and the private and philanthropic sectors to identify and address the critical issues in cancer prevention, research, and care to drive new actions and collaborations toward ending cancer as we know it.

Through these collaborations, the initiative intends to create a renewed sense of urgency around the need to expedite cancer research, care resources, data sharing, and patient navigation. The goal? To reimagine how the government, academia, nonprofits, and the private sector can better organize their resources and systems to collaborate to take on cancer.

Ms Johnston recently attended a Biden Cancer Initiative Advisory Board meeting. “Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.”

Related Articles
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
|
Web Exclusives
Lung cancer is the second most frequently diagnosed malignancy in both men and women (following prostate and breast cancer, respectively), and the leading cause of cancer deaths overall. Non–small-cell lung cancer (NSCLC) is the most common type, with the more aggressive small-cell lung cancer (SCLC) making up approximately 10% to 15% of cases.
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Yvette Florio Lane
|
Web Exclusives
On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval to the novel antibody-drug conjugate polatuzumab vedotin-piiq (Polivy; Genentech) in combination with bendamustine plus rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least 2 previous therapies. This is the first chemoimmunotherapy regimen approved for use in patients with DLBCL who are ineligible for hematopoietic stem-cell transplantation.
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
|
Web Exclusives
On May 3, 2019, the US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Patients should be selected for treatment with this agent based on an FDA-approved companion diagnostic test (Ventana Medical System’s PATHWAY anti-HER-2/neu [4B5] Rabbit Monoclonal Primary Antibody assay or INFORM HER2 Dual ISH DNA Probe Cocktail assay).
Cite this Article

Journal of Oncology Navigation & Survivorship. 2018;9:192.

Last modified: June 13, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code